Please assess the completion status of the following clinical trial:

Trial Title: Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* single enhancing lesion of the brain with MRI appearance consistent with GBM~* Must be appropriate for Gliadel® wafer implant~* Pathologic confirmation of GBM~* no gross residual tumor found on the immediate postoperative MRI scan~* Volumetric measurements of the resection cavity margin being \< 50 cc~* Karnofsky performance status (KPS) 80% or better~* Must be able to undergo MRI imaging with gadolinium~* Willingness to have follow up visits at Barrow Neurological Institute(BNI)~Exclusion Criteria:~* multi-focal tumors~* tumors which extend across the corpus callosum,~* residual nodular disease~* Tumors, with a contraindication to Gliadel® implant, such as an anticipated extensive ventricular opening resulting from complete resection.~* Tumor measuring greater than 50cc in volume (on post-operative scan) Volume \< 50 cc if volume if a significant volume of eloquent tissue is included in the proposed treatment volume~* Unable to undergo MRI with gadolinium~* History of cancer within 2 years of GBM diagnosis (basal and squamous cell skin cancers are allowed)~* Patient is not willing to follow up at BNI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GammaKnife(R) stereotactic radiosurgery (Type: EXPERIMENTAL): Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
- Standard fractionated radiation therapy (Type: ACTIVE_COMPARATOR): Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).